Viral Resistance Analyses From the Remdesivir Phase 3 Adaptive COVID-19 Treatment Trial-1 (ACTT-1).
J Infect Dis
; 228(9): 1263-1273, 2023 11 02.
Article
in En
| MEDLINE
| ID: mdl-37466213
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
COVID-19
Type of study:
Clinical_trials
Limits:
Adult
/
Child
/
Humans
Language:
En
Journal:
J Infect Dis
Year:
2023
Document type:
Article
Affiliation country:
United States
Country of publication:
United States